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Influenza A H5N1
Detection 
Enders K.O. Ng,* Peter K.C. Cheng,* 
Antia Y.Y. Ng,* T.L. Hoang,† and Wilina W.L. Lim* 
We developed a sensitive and rapid real-time reverse
transcription-polymerase chain reaction (RT-PCR) assay to
detect influenza A H5N1 virus in clinical samples. This
assay was evaluated with samples from H5N1-infected
patients and demonstrated greater sensitivity and faster
turnaround time than nested RT-PCR.
The first outbreak of highly pathogenic influenza AH5N1 virus in humans occurred in Hong Kong in 1997
and 6 people with confirmed infection died (1). In
February 2003, 2 persons who had traveled to Fujian
Province in China were hospitalized in Hong Kong with
H5N1 infection (2). Early in 2004, an influenza A H5N1
outbreak emerged in Vietnam and Thailand that caused
death in humans and epidemics in the poultry industry
(3–5). The recent recurrence of influenza A H5N1 prompt-
ed us to highlight the need for a highly sensitive, accurate,
and rapid diagnostic test for the infection. Such a test
would be important, not only in infection control but also
to facilitate early antiviral therapy. Conventional diagnos-
tic tools, cell culture, and serologic testing require from 2
days to 2 weeks for results; thus, they are less useful in
making therapeutic and infection control decisions. On the
other hand, commercially available rapid antigen tests
such as Directigen Flu A+B (Becton Dickinson, Sparks,
NJ, USA) or Binax NOW (Binax Inc., Portland, ME, USA)
are rapid and simple, but subtyping of viruses is not feasi-
ble. Molecular diagnosis of influenza by reverse transcrip-
tion-polymerase chain reaction (RT-PCR) provides a
sensitive and rapid means for detection and has facilitated
the typing and subtyping of viruses. Previously,
researchers developed tests to detect H5N1 virus by using
conventional RT-PCR (6–8) and confirmed the results by
Southern blot analysis (6) or restriction fragment length
polymorphism–based strategy (8). Although real-time RT-
PCR based on the avian H5 gene was developed, the assay
has not been evaluated on human clinical specimens (9).
We developed a highly sensitive, rapid, and accurate real-
time RT-PCR assay to directly diagnose influenza A sub-
type H5 in human clinical samples. When we evaluated
this system using clinical samples from patients infected
with H5N1 in Hong Kong and Vietnam, we found it was
more sensitive and faster in detecting the virus than the
nested RT-PCR that we used previously (3).
The Study
Our real-time RT-PCR is a multiplex assay that
employs a mixture of 2 sets of inhouse designed primers
and dual-labeled fluorescent probes that specifically target
2 different regions of the HA gene of H5N1. The primer
and probe sets were designed by using the Primer Express
software program (Applied Biosystems, Foster City, CA,
USA). Both primer and probe sets designs were based on
some of the sequences of the recent Vietnam H5N1 strains
(e.g., A/Viet Nam/1194/2004). Multiple alignments of pre-
vious and recent H5N1 strains were performed to mini-
mize primer mismatch. Multiplex performance was
maximized by selecting primers and probes with uniform
melting temperatures and minimal cross-hybridization
potential. The primer and dual-labeled fluorescent probe
sequences are shown in Table 1. This assay is a 2-step,
real-time RT-PCR system. Viral RNA is reverse tran-
scribed with random hexamers, followed by real-time
PCR. Briefly, viral RNA was extracted from 140 µL clini-
cal specimens in phosphate-buffered saline or viral trans-
port medium with a viral RNA mini kit (Qiagen, Hilden,
Germany) and a final elution with 60 µL AVE buffer.
Reverse-transcriptase reactions contained 4.2 µL RNA
extract, 2 µL 10× PCR buffer (Applied Biosystems), 2.5
µM random hexamer primers (Applied Biosystems), 20
units RNase inhibitor (Applied Biosystems), and 1 µL (50
U) MuLV reverse transcriptase (Applied Biosystems).
Reverse-transcriptase reactions were performed at
room temperature for 10 min, then at 42°C for 30 min and
at 95°C for 5 min. Five microliters of the cDNA was then
used for amplification in the real-time PCR assays. Real-
time PCR was carried out with a LightCycler (Roche
Diagnostics GmbH, Mannheim, Germany). The real-time
PCR reactions (total volume 20 µL) contained 2 µL
LightCycler DNA Master Hybridization Probes reaction
mix (Roche Diagnostics GmbH), 3 mmol/L magnesium
chloride, 250 nmol/L each of the 4 primers, and 125
nmol/L each of the dual-labeled fluorescent probes. The
thermal profile used was initiated at 95°C for 10 min (pre-
amplification hot start), followed by 50 cycles of PCR at
95°C for 10 s (denaturation), 56°C for 15 s (annealing),
and 72°C for 12 s (extension). At the end of each anneal-
ing step, the fluorescent signal of each reaction was meas-
ured at a wavelength of 530 nm with the LightCycler
fluorimeter. Precautions were taken to prevent cross-con-
tamination of PCR (10).
To test for cross-reactivity, RNA was extracted from
isolates or persons with human influenza A H1, H3, H9
subtypes; influenza B; human CoV 229E and OC43; respi-
ratory syncytial virus; rhinoviruses; and enteroviruses. The
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RNA was then tested by the described real-time RT-PCR.
The results showed that the assay was specific for the H5
subtype. The detection sensitivity of the real-time assay
was compared with that of 2 other assays by analyzing a
serial 10-fold dilution of viral stock with 108 tissue culture
infective dose (TCID)50/mL of rhabdomyosarcoma
cell–culture fluid of a recent H5N1 isolate (A/Viet
Nam/1194/2004). The results showed that our real-time
RT-PCR assay was the most sensitive of the 3 assays, 10-
fold more sensitive than nested RT-PCR (Table 2). We ana-
lyzed 18 archived respiratory samples collected <10 days
after onset of illness from 13 confirmed H5N1–infected
patients from Hong Kong in 1997 and 2003 and 10 sam-
ples collected on an unknown onset day of illness from 5
confirmed H5N1–infected patients from Vietnam in 2004.
All samples were confirmed as H5N1 positive by virus iso-
lation and characterization. Our findings demonstrated that
the detection rate of the RT-PCR assay was 100% (28 of 28
samples), whereas that of the nested RT-PCR was 89% (25
of 28 samples). This finding indicates that the real-time
assay shows similar or greater sensitivity than the nested
RT-PCR. Furthermore, the H5 viral load of the archived
clinical samples was determined by a standard curve
obtained by plotting from the same series of 10-fold dilu-
tions of virus stock. Viral load analysis showed that the
concentration of H5N1 RNA in those clinical specimens
ranged from 101 to 106 TCID50/mL. Based on the serial
sample analysis of 2 patients, the viral load of patient 1
increased 5-fold from day 0 to day 3, whereas the viral
load of patient 2 dropped 3-fold from day 4 to day 7
(Figure). Because a limited number of samples were ana-
lyzed, the peak of viral load cannot be determined. Studies
have reported that the viral load in nasopharyngeal aspirate
of the H5N1 patients was lower than in those with H3N2
infection in 2003 (11). To determine whether the viral load
of H5N1 patients in 1997 and 2004 is different from that
of H3N2 patients, clinical specimens from these 2 groups
of patients were analyzed by using a quantitative real-time
RT-PCR assay that targeted the M gene of influenza A
(12). Similarly, viral load was determined by a standard
curve obtained by plotting from series of 10-fold dilutions
of a H3N2 virus stock. The mean viral load of 22 patients
with H3N2 virus infection was 1.5 × 106 TCID50/mL,
whereas the mean viral load of H5N1 patients was 1.6 ×
105 TCID50/mL in both 1997 and 2004. Thus, 10-fold
lower viral loads were observed in H5N1 patients in both
1997 and 2004 (t test, p<0.05). These data are consistent
with previous data that showed rapid diagnostic methods
for influenza are less sensitive for H5N1 detection, likely
due to lower viral loads.
Conclusions 
In this study, we demonstrated that our new multiplex
real-time RT-PCR assay that specifically targets 2 different
regions of the H5 gene is more sensitive than nested RT-
PCR and even more sensitive than real-time RT-PCR with
a single set of primers and probes (unpub. data). Our data
prove that the assay is specific for H5 subtype and capable
of detecting and quantifying H5 RNA in clinical samples
from patients obtained during different outbreaks (1997,
2003, and 2004). Unlike nested RT-PCR, the real-time
assay not only reduces the risk for contamination but also
reduces turnaround time to 1–2 hours, 3 times faster than
the nested RT-PCR. In conclusion, our study demonstrates
that our real-time RT-PCR assay is rapid, specific, and rel-
atively sensitive for directly detecting influenza A subtype
H5 virus and may be useful in routine diagnostic testing.
DISPATCHES
1304 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 8, August 2005
Dr. Ng is a research officer at the Virology Division of the
Centre for Health Protection, Department of Health, Hong Kong
Special Administrative Region, China. His research focuses on
the molecular detection of human pathogens, especially viral
infectious agents.
References
1. Saw TA, Lim W, Shortridge K, Tam J, Liu KK, Mak KH, et al.
Isolation of avian influenza A(H5N1) viruses from humans—Hong
Kong, May–December 1997. MMWR Morb Mortal Wkly Rep.
1997;46:1204–7.
2. World Health Organization. Influenza A (H5N1), Hong Kong Special
Administrative Region of China. Wkly Epidemiol Rec.
2003;78:49–56.
3. Tran TH, Nguyen T, Nguyen TD, Loung TH, Pham PM, Nguyen VC,
et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J
Med. 2004;350:1179–88.
4. Chotpitayasunondh T, Lochindarat S, Srisan P, Chokepaibulkit K,
Weerakul J, Maneeratanaporn M, et al. Cases of influenza A
(H5N1)—Thailand, 2004. MMWR Morb Mortal Wkly Rep.
2004;53:100–3.
5. Viseshakul N, Thanawongnuwech R, Amonsin A, Suradhat S,
Payungporn S, Keawchareon J, et al. The genome sequence analysis
of H5N1 avian influenza A virus isolated from the outbreak among
poultry populations in Thailand. Virology. 2004;328:169–76.
6. Yuen KY, Chan PK, Peiris M, Tsang DN, Que TL, Shortridge KF, et
al. Clinical features and rapid viral diagnosis of human disease asso-
ciated with avian influenza A H5N1 virus. Lancet. 1998;351:467–71.
7. Munch M, Nielsen LP, Handberg KJ, Jorgensen PH. Detection and
subtyping (H5 and H7) of avian type A influenza virus by reverse
transcription-PCR and PCR ELISA. Arch Virol. 2001;146:87–97.
8. Cooper LA, Subbarao K. A simple restriction fragment length poly-
morphism-based strategy that can distinguish the internal genes of
human H1N1, H3N2, and H5N1 influenza A viruses. J Clin
Microbiol. 2000;38:2579–83.
9. Spackman E, Senne DA, Myers TJ, Bulaga LL, Garber LP, Perdue
ML, et al. Development of a real-time reverse transcriptase PCR
assay for type A influenza virus and the avian H5 and H7 hemagglu-
tinin subtypes. J Clin Microbiol. 2002;40:3256–60.
10. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature.
1989;339:237–8.
11. Peiris JS, Yu WC, Leung CW, Cheung CY, Ng WF, Nicholls JM, et
al. Re-emergence of fatal human influenza A subtype H5N1 disease.
Lancet. 2004;363:617–9.
12. Ward CL, Dempsey MH, Ring CJ, Kempson RE, Zhang L, Gor D, et
al. Design and performance testing of quantitative real time PCR
assays for influenza A and B viral load measurement. J Clin Virol.
2004;29:179–88.
Address for correspondence: Wilina W.L. Lim, Virology Division, Public
Health Laboratory Centre, 382 Nam Cheong St, Shek Kip Mei, Kowloon,
Hong Kong; fax: 852-23195989; email: wllim@pacific.net.hk
Influenza A H5N1 Detection
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 11, No. 8, August 2005 1305
Figure. Serial quantitative analysis for influenza A H5N1 virus in
respiratory samples from 2 patients with H5N1 in 1997 by quanti-
tative real-time reverse transcription–polymerase chain reaction
assay. TCID50, 50% tissue culture infective dose.
